EGFR and breast carcinoma: Similar results were observed in MCF7/PalbR and T47D/PalbR cells upon exposure to the EGFR inhibitor gefitinib (data not shown), in accordance with previous studies indicating that EGFR inhibition may blunt the proliferation of palbociclib resistant breast cancer cells [79].